PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29039537-0 2017 Juglone potentiates TRAIL-induced apoptosis in human melanoma cells via activating the ROS-p38-p53 pathway. juglone 0-7 tumor protein p53 Homo sapiens 95-98 32377702-9 2020 In conclusion, juglone potentiated BRAF inhibitor-induced apoptosis in resistant melanoma cells, and these effects occurred partially through ROS and the p38-p53 pathway, suggesting the potential of juglone as a sensitizer to BRAF inhibitors in the treatment of melanoma. juglone 199-206 tumor protein p53 Homo sapiens 158-161 31283929-0 2019 ROS -mediated p53 activation by juglone enhances apoptosis and autophagy in vivo and in vitro. juglone 32-39 tumor protein p53 Homo sapiens 14-17 29039537-10 2017 In conclusion, juglone potentiated TRAIL-induced apoptosis in melanoma cells, and these effects were partially mediated through the ROS-p38-p53 pathway. juglone 15-22 tumor protein p53 Homo sapiens 140-143 32377702-0 2020 Juglone potentiates BRAF inhibitor-induced apoptosis in melanoma through reactive oxygen species and the p38-p53 pathway. juglone 0-7 tumor protein p53 Homo sapiens 109-112 32377702-7 2020 Moreover, juglone combined with PLX4032 markedly increased the intracellular level of reactive oxygen species (ROS) and activated p38 and p53, as compared with juglone alone or PLX4032 alone. juglone 10-17 tumor protein p53 Homo sapiens 138-141 29039537-8 2017 However, exposure to TRAIL in combination with juglone markedly increased the production of ROS, activated p38 and increased p53, compared with the cells treated with either juglone or TRAIL alone. juglone 47-54 tumor protein p53 Homo sapiens 125-128 16271620-6 2005 Surprisingly, juglone caused a drastic reduction of the basal level of p53 in human fibroblasts and this loss could not be fully rescued by proteasome and calpain I inhibitors. juglone 14-21 tumor protein p53 Homo sapiens 71-74